© 2026 Sinochem Nanjing Corporation,
All Right Reserved
People first learned about bile acids centuries ago, poking around in the chemistry of animal livers and gallbladders. Chenodeoxycholic acid, or CDCA, came into the scientific spotlight in the early 20th century when biochemists began isolating and characterizing the different molecules that help digest fats. Researchers found CDCA in goose bile, and the name stuck: “cheno” refers to geese. Doctors and pharmacists soon caught onto its therapeutic tricks, especially in the treatment of gallstones. Studying its pathways unlocked insights about cholesterol and liver function, highlighting a deep link between ancient remedies and modern pharmaceuticals. In the 1970s, the approval of chenodeoxycholic acid for dissolving certain gallstones added to its pharmaceutical reputation. The development didn’t stop there. Scientists kept digging, mapping its metabolic routes and figuring out how it interacts with other bile acids.
Chenodeoxycholic acid stands out as one of the major bile acids found in humans and many animals. It shows up as a white, crystalline powder with a faint, bitter taste that gives away its origins. Commercially, firms extract or synthesize it for medicinal, research, and industrial use. Whether it comes from natural or synthetic processes, it serves as a raw material for drug manufacturing, a reagent for biochemical assays, and sometimes as a nutraceutical component. Most notably, doctors prescribe CDCA for dissolving cholesterol gallstones and treating rare metabolic disorders, including cerebrotendinous xanthomatosis (CTX). Laboratories also use it to explore cellular metabolism and digestive health.
The molecular formula for chenodeoxycholic acid reads C24H40O4, with a molecular weight clocking in at 392.57 g/mol. The structure shows clear steroid hallmarks, with a backbone of four interconnected rings and two hydroxyl groups at carbon positions 3 and 7. Those hydroxyls explain why the acid dissolves just a bit better in alcohol and alkaline solutions than in pure water; expect only slight solubility in water but much higher solubility in organic solvents like methanol or ethanol. CDCA’s melting point sits between 165 to 168 °C. The molecule’s solid-state form holds up well under room temperature, and it won’t easily volatilize. Its amphipathic properties—meaning it carries both water-loving and fat-loving parts—help it emulsify fats in the digestive tract, an essential step in nutrition and metabolism.
Pharmaceutical-grade chenodeoxycholic acid usually ships with strict analysis certificates. Purity often exceeds 98%, with controlled limits for related bile acids, residual solvents, and heavy metal contaminants. Identification calls for spectroscopic checks—like infrared (IR) spectra—and chromatographic purity measurements, such as HPLC or TLC profiles. Heavy metal contamination (lead, arsenic, mercury) must stay below set thresholds, sometimes as low as 10 ppm. Labeling requirements direct users to store the powder in tightly-closed containers, away from direct sunlight and humidity, often at temperatures under 25°C. Safety data sheets communicate risks, including skin or eye irritation, and advise correct handling, especially in lab or manufacturing settings.
Chenodeoxycholic acid used to come mainly from animal bile—often goose or pig—by extracting and then chemically purifying the mixture of bile acids. Later advances allowed for de novo synthesis or semi-synthetic steps starting with cholic acid, another common bile acid. Chemical dehydroxylation, separation by crystallization, and further purification steps refine the product. Industrial preparations might favor enzymatic conversion using genetically engineered microorganisms, which mimic natural metabolic pathways to yield higher volumes with fewer processing byproducts. After isolation, refiners recrystallize CDCA several times to reach pharmaceutical standards. Each method aims for high purity to avoid impurities that might trigger side effects.
CDCA holds potential as a building block for further pesticide, pharmaceutical, and biochemical work. Transforming the hydroxyl groups to other functional groups shifts physiological effects, letting scientists make powerful derivatives like ursodeoxycholic acid. Acylation, oxidation, or esterification expand the menu of possible compounds derived from the base skeleton. In the lab, mild oxidants or strong acids can adjust hydroxyl or carboxylic positions, so researchers can tailor molecules to study or modulate bile acid signaling, absorption, and excretion. Some of these analogs have entered clinical trials to see if slight modifications can improve efficacy or safety for patients with digestive, hormonal, or neurodegenerative diseases.
Beyond “chenodeoxycholic acid,” the molecule follows a long trail of other names. You might see “chenocholic acid,” “3α,7α-dihydroxy-5β-cholan-24-oic acid,” or sometimes just the abbreviation “CDCA.” Pharmaceutical products rely on names like Chenofalk or Chenodal, with preparations varying in tablet, capsule, or powder form. In biochemistry labs, suppliers list product numbers attached to the chemical’s name for easy referencing. These synonyms sometimes spark confusion, so double-checking chemical structure and registered numbers proves essential for getting the right compound for a job.
In manufacturing or research settings, clear operational steps limit the risk tied to chenodeoxycholic acid. The fine powder can cause respiratory, skin, or eye irritation when it gets airborne. Lab workers don gloves, goggles, and sometimes filtration masks to keep particles out of the air and away from sensitive tissues. Spills clean up best with damp wipes followed by thorough disposal per hazardous waste guidelines. Regulatory agencies in the U.S., Europe, and Asia keep strict controls over human-use products, enforcing testing for purity, microbial load, and chemical stability before a lot earns its way onto pharmacy shelves. Continuous monitoring, both during production and storage, guards against contamination that could compromise drug safety.
Chenodeoxycholic acid’s largest use lies in medicine. Doctors prescribe it for dissolving small and moderate cholesterol gallstones in patients unsuitable for surgery or anesthesia. The effect works best for stones not packed with calcium, as these resist chemical dissolution. Specialists treating rare lipid storage diseases also draw on CDCA’s power. People with CTX, who lack normal bile acid synthesis, rely on daily doses of CDCA to restore a healthier metabolic balance and slow down neurological symptoms. Outside the hospital, nutrition researchers examine how CDCA shapes lipid metabolism and gut health. Some new studies look at its influence on metabolism, immunity, and even gut-brain signaling, framing it as a molecule of interest not only for treating disease but also for understanding how our bodies handle fats, cholesterol, and hormones.
The last few decades have brought a surge of interest in bile acid biology, with chenodeoxycholic acid at the forefront. Genomic and metabolomic approaches uncover how this hormone-like molecule interacts with nuclear receptors (like FXR and TGR5) to regulate cholesterol, glucose, and energy homeostasis. Mouse models and clinical trials give clues about new uses. Beyond gallstones, teams explore CDCA for use in managing nonalcoholic fatty liver disease, cholestatic liver conditions, and even rare genetic syndromes. The connections between CDCA signaling and cancer, inflammation, or metabolic syndrome draw Big Pharma and biotech startups toward the field, betting that compounds inspired by CDCA could unlock treatments for complex multi-system disorders.
Therapeutic doses of CDCA work for most, but excessive use or unregulated exposure doesn’t sit well with the human body. Toxicity research points toward potential problems at higher doses, where patients develop diarrhea, liver enzyme spikes, or in rare cases, worsened liver injury. Long-term use demands monitoring of liver function, and certain patients—like pregnant women or those with liver failure—shouldn’t receive CDCA. Animal studies focus on chronic effects, including carcinogenic or mutagenic risks. Newer research pushes for better biomarkers to predict adverse outcomes earlier, giving doctors and patients more confidence about when to prescribe or withhold treatment.
Chenodeoxycholic acid moves beyond its roots in bile and gallstones. With advances in synthetic chemistry and bioengineering, scientists race to invent new derivatives that hit metabolic and immune pathways with more precision and fewer side effects. Some labs work on delivering bile acid analogues via nanotechnology to target certain tissues—offering hope for conditions like fatty liver, diabetes, or even some neurological diseases grounded in metabolic shifts. The story of CDCA’s future links tightly to research on the gut microbiome, since bacteria turn bile acids into dozens of signaling molecules that interact with our health in still-mysterious ways. If breakthroughs keep coming, chenodeoxycholic acid could open doors to new diagnoses, new drugs, and a deeper picture of how the liver, gut, and brain keep us in balance. The chemistry of an old molecule keeps fueling discoveries for modern medicine and biotechnology.
Chenodeoxycholic acid has a name that sounds straight out of a chemistry textbook, but for people with rare health conditions, it can mean the difference between constant discomfort and a shot at normal life. Doctors often reach for this compound to help patients whose bodies have trouble breaking down certain types of fats. I remember reading about patients with gallstones or those struggling with genetic disorders—this acid has given them real hope where older treatments didn’t.
Surgery has long stood as the fix for gallstones, yet it isn’t always possible or safe. Chenodeoxycholic acid offers another option. By breaking up cholesterol stones in the gallbladder, this compound can give relief without forcing a person into an operating room. It works by changing how the body processes cholesterol, making stones shrink over time. Several major studies have tracked people over months as their medical teams monitored the size of their gallstones, and doctors noticed not just improvement but true resolution in plenty of cases. The treatment isn’t fast, but for people avoiding surgery, it’s life-changing.
Outside gallstones, there’s an even rarer use: children born with inherited disorders like cerebrotendinous xanthomatosis (CTX). Without chenodeoxycholic acid, these kids risk severe neurological decline. Their bodies can’t make or process bile acids the usual way, so toxins build up. Giving them this compound gives their system what it needs so damage doesn’t keep piling on. Seeing even small improvements in these children’s lives shows how medication goes beyond chemical reactions; it can help real families get back moments they thought they’d lost.
No one wants to feel like a guinea pig during treatment. Valid clinical data matters. Researchers have backed up chenodeoxycholic acid’s benefits, especially for gallstones and CTX. Healthcare regulators keep testing every batch to make sure it meets strict safety and purity standards. When doctors recommend this compound, they pull from years of studies and real-world outcomes, not just theory. It’s satisfying to know that the pills that land in a pharmacy are tested and backed by careful work at every stage.
There are still challenges in getting the medication to everyone who needs it, especially when dealing with rare diseases. Sometimes it’s about cost, other times it’s navigating rules that control how doctors prescribe this kind of specialized drug. Advocacy groups now push for better access and help raise awareness. There’s also ongoing work on insurance issues, because nobody should have to skip care for something a tablet could set right.
The future holds promise. Researchers study how chenodeoxycholic acid and similar compounds help other liver and bile diseases. They’re looking for better ways of delivering and dosing the medication so people need fewer pills and face fewer side effects. As a society, we owe it to families dealing with difficult diagnoses to push forward—supporting strong science and building bridges so treatments reach every person who needs them.
Doctors often prescribe chenodeoxycholic acid for rare liver conditions, like cerebrotendinous xanthomatosis (CTX). This isn’t some over-the-counter supplement you toss in with your daily vitamins. The way you take it matters — a lot. People living with CTX or certain gallstone issues rely on this medicine to slow down disease damage, keep symptoms at bay, and maintain their energy. But improper use brings down its benefits and can actually cause more harm than good.
Doctors usually give clear, no-nonsense instructions. Take it by mouth, stick to the dose, and swallow the tablet whole. Crushing or splitting tablets can mess with how your body absorbs the medicine, which can mean less effective treatment or more side effects. Doctors might ask you to take it with food, to avoid stomach upset. I’ve talked with patients who started the medicine on an empty stomach and regretted it — nausea, cramps, even vomiting struck not long after. That kind of discomfort makes people want to quit, but it usually gets better once they pair their pill with a real meal.
Skipping doses or doubling up rarely brings good news. Blood levels get thrown off, which can make symptoms worse or spark new ones. Monitoring matters. The rare nature of conditions needing chenodeoxycholic acid means healthcare teams almost always want to see you once treatment starts. Expect blood work and doctor visits — these habits keep side effects in check and help tweak your dose for results, not just hope.
All medicines carry risk, and this drug walks no different path. Upset stomach ranks high on the list, as does diarrhea. In rare cases, patients run into liver changes. That’s one reason doctors keep an eye on your labs and ask lots of questions about your energy, mood, and digestion after starting. Ignoring strange symptoms doesn’t pay off; talking to your provider early keeps small problems from growing into far bigger ones.
Storing chenodeoxycholic acid in a cool, dry spot matters. People sometimes forget the basics, like keeping medicine away from kids and pets or checking expiration dates. It’s easy to treat prescriptions as afterthoughts, especially with rare drugs, but expired or improperly stored medicines often lose strength or cause problems you never saw coming.
Open, honest conversations with healthcare teams keep treatment on track. Patients sometimes hesitate to mention symptoms or admit missed doses — fear of scolding holds them back. My experience says the truth is always better. Doctors can’t fix what they don’t know. They adjust plans, suggest simple fixes (food instead of an empty stomach), or sometimes switch medicines altogether if side effects get too tough.
Access still poses challenges. Most people don’t encounter chenodeoxycholic acid unless diagnosed with something rare. Insurance hurdles, pharmacy delays, and lack of clear patient info cause confusion and frustration. Bigger pharmacies, clearer prescription packaging, and digital alerts could help. Health systems do best when they treat pills for rare conditions with the same urgency as common ones.
Safe, effective use of chenodeoxycholic acid depends on honest communication, familiarity with your own medication, and a dose of patience as your body adjusts. The best results come from teamwork — patient and provider both in the know, working together, and not leaving questions unasked.
Anyone handed a prescription for chenodeoxycholic acid will probably scan the list of possible side effects and feel a bit uneasy. Doctors often highlight how this medicine helps dissolve certain gallstones and treat rare liver conditions like cerebrotendinous xanthomatosis. But in practice, real people struggle with the side effects in ways pamphlets rarely capture. My time around hospital wards has taught me that even drugs with long histories carry surprises for patients and new lessons for clinicians.
Stomach issues top the list. Nausea and diarrhea often push people to question if their treatment is worth it. Practically everyone wants to know how to keep working or travel safely when their day might be derailed by a sudden need for a bathroom. Some folks develop abdominal pain or cramps, magnified by diet and stress. These can look mild on paper but disrupt routines. Dealing with unpredictable symptoms can make people reluctant to stick with their treatment, which sometimes triggers bigger health setbacks.
A less common but well-known concern is liver irritation. Doctors monitor liver enzymes because abnormal blood tests can mean inflammation is brewing. The conversations I’ve had with patients show how numbers on a lab report translate to fear about long-term organ damage or new illnesses.
Chenodeoxycholic acid rarely causes allergic reactions, but any history of hives or shortness of breath after taking it needs careful attention. Swelling, trouble swallowing, or a rash can become emergencies fast. Over the years, I’ve seen more worry about these rare outcomes than about the drug’s intended purpose.
The mental side shouldn’t be ignored. Some people report feeling mood swings or just not quite themselves. Whether it’s the result of physical discomfort or the stress of managing an uncommon disease, these changes matter. Managing side effects involves supporting the whole person, not just treating numbers in a chart.
Trust builds when health providers talk openly about side effects and listen closely. I’ve seen more success when people felt heard about the little things: fatigue after each dose, worries about social plans, anxiety over long-term risks. It’s easy to underestimate the exhaustion that comes from needing to read ingredient lists or plan errands around restroom stops. Empathy in those conversations leads to better choices, and helps keep folks engaged with their care plans.
Doctors need honest feedback from people actually taking chenodeoxycholic acid. Tracking symptoms day by day helps spot patterns, as does involving pharmacists and nutritionists who can look for interactions and dietary triggers. Adjusting how or when someone takes the drug—sometimes with food, other times in smaller doses throughout the day—can make it easier on the gut.
Every story is different. Side effects should be a starting point for ongoing conversations, not a reason to avoid treatment. Connecting people with support groups can make a difference, swapping advice and encouragement that goes beyond any package insert.
Learning what really matters to someone living with side effects—whether it’s peace of mind, stable routines, or confidence at work—shapes the best possible care. Listening goes further than any standard warning label, and that’s where real improvement begins.
Most people haven’t heard much about chenodeoxycholic acid, unless they’ve dealt with rare disorders like gallstones or certain liver problems that doctors sometimes treat with this compound. That probably says a lot on its own: not enough research covers its use by pregnant or breastfeeding women. Doctors and parents both end up searching for answers and walking into a gray zone.
I remember my cousin faced a tough choice during her pregnancy after she got diagnosed with a liver issue. Her doctor brought up chenodeoxycholic acid as a part of the discussion. She scoured the internet, called specialists, and learned pretty fast: there’s a gap in the data. Most studies either focused on animals or included very few pregnant women, if any. The Food and Drug Administration classifies chenodeoxycholic acid under “unknown risk” for pregnancy. That label means we just don’t know enough about how it could affect a fetus or a newborn.
Medicine during pregnancy asks for a heavy dose of caution. Some drugs easily cross the placenta, making their way to the baby. Chenodeoxycholic acid belongs to a group called bile acids—natural chemicals the body uses to digest fat—but boosting their levels could shift the body’s delicate balance, especially during pregnancy. Research hasn’t firmly answered questions about the risk of birth defects or other complications.
During breastfeeding, the puzzle gets even murkier. We just don't have solid proof to show whether this substance gets into breast milk, or how it would affect a newborn’s developing gut and liver. One clinical guideline I read recommended avoiding chenodeoxycholic acid if possible when breastfeeding, simply because nobody can promise it’s safe. Responsible healthcare workers admit they don’t want to gamble with a baby’s health.
One thing stands out more than any specific risk: open conversations with healthcare teams save grief and guesswork. Obstetricians and pharmacists keep up with the latest drug reports. They know which medicines have safer alternatives or tried-and-tested histories for use during pregnancy or lactation. Women shouldn’t feel awkward about pressing for a full list of pros and cons—doctors expect and even welcome these questions. Anyone facing the decision to start a drug like chenodeoxycholic acid should ask every tough question that comes to mind.
Research into medication safety for pregnant and breastfeeding women falls behind compared to other fields. One reason: drug companies and scientists worry about the unknown risks themselves, plus the ethics of including vulnerable groups in trials. People need more studies, not just statistics scraped from old prescription records. Until the medical community invests more time and resources, everyday patients and families operate with faded roadmaps.
There’s room for progress. Patient stories, national registries, and collaborative research could all help fill gaps. In the meantime, caution and curiosity need to guide personal decisions. I’ve learned the hard way that guessing with medication just isn’t worth it, especially with something as important as a pregnancy or a newborn.
Chenodeoxycholic acid sounds like something you'd learn about in an advanced chemistry class, but many people with liver or gallbladder issues know it well. It’s one of the main bile acids your liver makes naturally and for some rare conditions, doctors prescribe it to fix problems related to cholesterol gallstones or certain genetic liver diseases. Once a medicine moves out of the textbook and into the medicine cabinet, drug interactions start to matter—a lot more than most realize.
People who rely on chenodeoxycholic acid often take other medications, either for the underlying liver issue or because of the ripple effect chronic illness causes through the whole body. Every time I speak with someone dealing with a rare liver disease, their pillbox looks more complicated each year. Drug interactions can sneak up, changing how much of each medicine builds up in the body or how they work—sometimes without any obvious symptoms at first.
With chenodeoxycholic acid, the biggest concerns pop up with drugs that affect the liver. That includes common statins for cholesterol, some diabetes medications like glipizide and glyburide, and even certain antibiotics. These medicines can share the same liver enzymes, which means one drug can slow down or speed up how another one gets broken down. The result: more side effects, or less help from the treatments being used for serious, even life-threatening, conditions.
Many people trying to manage cholesterol or heartburn keep cholestyramine or antacids close by, but they could trip up the body’s absorption of chenodeoxycholic acid. Doctors have seen cases where these drugs physically bind the bile acid in the gut, making it less useful. The problem isn’t abstract—it means less medicine gets in, so symptoms don’t improve. I’ve had people tell me they had no idea “harmless” remedies like antacids could actually undo their main treatment. This doesn’t always come up in a rushed appointment unless someone asks directly.
Estrogen, found in hormone replacement therapies and birth control, can block the way bile acids work. Studies show women taking both might see slower bile flow or changes in cholesterol processing—not ideal for someone already struggling with these problems. I’ve heard more than once from patients who ended up with unexpected lab results or feeling worse after starting a new hormonal medication, only to find out the clash was hidden in the fine print all along.
The safest path always goes through open conversations at every checkup. Pharmacists catch many mistakes, but it pays for patients to bring their full list of pills—prescriptions, vitamins, and over-the-counter fixes—to each doctor visit. Updating that list in every conversation keeps surprises away. Lab work helps too. Regular blood tests keep an eye on liver markers and cholesterol so problems with drug interactions show up early, not months later.
Doctors can switch medicines if clashes show up. They can also change the timing of doses. Spacing apart troublesome drugs by a few hours keeps them from interfering in the digestive tract—a simple fix that goes a long way. For anyone using chenodeoxycholic acid long-term, check-ins with both doctors and pharmacists make a practical difference—not just for safety but for steady progress against tough liver or gallbladder conditions.
| Names | |
| Preferred IUPAC name | (4R)-4-[(3R,5R)-3,7-dihydroxy-5-cholan-24-oic acid |
| Other names |
Chenodiol Chenodesoxycholic Acid Cholurso CDCA Khenodeoksikholevaya kislota |
| Pronunciation | /ˌkiːnoʊˌdiːˌɒksaɪˌkɒlɪk ˈæsɪd/ |
| Identifiers | |
| CAS Number | 474-25-9 |
| Beilstein Reference | 136172 |
| ChEBI | CHEBI:35527 |
| ChEMBL | CHEMBL912 |
| ChemSpider | 2152 |
| DrugBank | DB06777 |
| ECHA InfoCard | 100.017.570 |
| EC Number | 3.6.3.13 |
| Gmelin Reference | 94119 |
| KEGG | C02528 |
| MeSH | D002784 |
| PubChem CID | 3523 |
| RTECS number | FF8580000 |
| UNII | PJ84Y047M5 |
| UN number | UN2811 |
| CompTox Dashboard (EPA) | DTXSID7020155 |
| Properties | |
| Chemical formula | C24H40O4 |
| Molar mass | 392.574 g/mol |
| Appearance | White crystalline powder |
| Odor | Odorless |
| Density | 1.284 g/cm³ |
| Solubility in water | Slightly soluble in water |
| log P | 3.8 |
| Vapor pressure | 2.83E-22 mmHg at 25°C |
| Acidity (pKa) | 6.23 |
| Basicity (pKb) | pKb = 15.85 |
| Magnetic susceptibility (χ) | -682.0e-6 cm³/mol |
| Refractive index (nD) | 1.523 |
| Viscosity | Viscous liquid |
| Dipole moment | 2.75 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 531.5 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -734.1 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -3521.6 kJ/mol |
| Pharmacology | |
| ATC code | A05AA03 |
| Hazards | |
| Main hazards | Harmful if swallowed. Causes serious eye irritation. Causes skin irritation. May cause respiratory irritation. |
| GHS labelling | GHS05, GHS07 |
| Pictograms | GHS05,GHS07 |
| Signal word | Warning |
| Hazard statements | Hazard statements: H315, H319, H335 |
| Precautionary statements | Precautionary statements: P264, P270, P301+P312, P330, P501 |
| Flash point | 155.3 °C |
| Lethal dose or concentration | LD50 oral rat 4 g/kg |
| LD50 (median dose) | 7300 mg/kg (Rat, oral) |
| PEL (Permissible) | PEL (Permissible Exposure Limit) for Chenodeoxycholic Acid: Not established |
| REL (Recommended) | 250 – 1,750 mg daily |
| IDLH (Immediate danger) | Not listed |
| Related compounds | |
| Related compounds |
Cholic acid Deoxycholic acid Ursodeoxycholic acid Lithocholic acid Hyodeoxycholic acid |
